Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 4
2012 3
2013 3
2014 9
2015 6
2016 5
2017 12
2018 15
2019 12
2020 12
2021 6
2022 11
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Schwerpunkt Harnblasenkarzinom.
Niegisch G. Niegisch G. Aktuelle Urol. 2022 Apr;53(2):135-136. doi: 10.1055/a-1696-7990. Epub 2022 Mar 28. Aktuelle Urol. 2022. PMID: 35344999 German. No abstract available.
Epigenetics of urothelial carcinoma.
Schulz WA, Koutsogiannouli EA, Niegisch G, Hoffmann MJ. Schulz WA, et al. Among authors: niegisch g. Methods Mol Biol. 2015;1238:183-215. doi: 10.1007/978-1-4939-1804-1_10. Methods Mol Biol. 2015. PMID: 25421661 Review.
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Fizazi K, et al. Among authors: niegisch g. Eur J Cancer. 2023 Oct;192:113258. doi: 10.1016/j.ejca.2023.113258. Epub 2023 Jul 27. Eur J Cancer. 2023. PMID: 37660438 Free article. Clinical Trial.
Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, Niegisch G, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C. Zschäbitz S, et al. Among authors: niegisch g. Eur Urol Open Sci. 2023 May 17;53:31-37. doi: 10.1016/j.euros.2023.04.018. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37441344 Free PMC article.
[Personalised medicine in urothelial bladder cancer].
Grunewald CM, Niegisch G. Grunewald CM, et al. Among authors: niegisch g. Aktuelle Urol. 2019 Sep;50(5):502-508. doi: 10.1055/a-0927-6725. Epub 2019 Jun 13. Aktuelle Urol. 2019. PMID: 31195416 Review. German.
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Among authors: niegisch g. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
103 results